Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background & Aims: We previously reported altered intestinal environmental features during HCV infection. Here, we aimed to characterize the gut-microbiota-liver axis in patients with chronic hepatitis C after a sustained virological response (SVR).

Methods: A total of 174 patients with HCV infection were enrolled in a cross-sectional study: 95 with chronic hepatitis (CH-HCV group) and 79 with cirrhosis or hepatocellular carcinoma (LC/HCC-HCV group). In addition, 75 post-SVR patients were included (CH-SVR group, n = 29; LC/HCC-SVR group, n = 46), along with 23 healthy individuals. A longitudinal study was subsequently conducted on 49 patients (CH, n = 29; LC/HCC, n = 20) with SVR at 24 and 48 weeks after the end of treatment. RNA sequencing was performed on 65 patients with HCV infection, 28 post-SVR patients, and 12 healthy controls.

Results: In the cross-sectional analysis, HCV eradication was associated with partial restoration of the dysbiotic gut microbiota, including reduced streptococcal overgrowth and an increase in the potentially beneficial genus , approaching levels seen in healthy individuals. Additionally, the aberrant fecal bile acid profile showed rebalancing, accompanied by restored expression of genes involved in the classical pathway of cholic and chenodeoxycholic acid biosynthesis. In the longitudinal study, improvements in liver fibrosis and function - evidenced by decreased Fibrosis-4 index and alanine aminotransferase levels - were significantly correlated with increased abundance of Blautia ( <0.0001 and = 0.0344, respectively), suggesting a beneficial role in liver recovery.

Conclusion: The gut-microbiota-liver axis is partially restored following HCV eradication, with recovery from liver damage associated with the resurgence of commensal Lachnospiraceae species.

Impact And Implications: This study offers significant insights into the gut-microbiota-liver axis in patients with chronic hepatitis C following a sustained virological response. The findings demonstrate that HCV eradication promotes partial restoration of the dysbiotic gut microbiota, particularly an increase in the beneficial genus , as well as a rebalancing of the fecal bile acid profile. These changes are closely associated with significant improvements in liver fibrosis and function, highlighting a potential role of the gut microbiota in liver recovery and regeneration.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355056PMC
http://dx.doi.org/10.1016/j.jhepr.2025.101494DOI Listing

Publication Analysis

Top Keywords

hcv infection
12
gut-microbiota-liver axis
8
chronic hepatitis
8
patients hcv
8
post-svr patients
8
healthy individuals
8
longitudinal study
8
patients
6
restoration gut-microbiota-liver
4
axis hepatitis
4

Similar Publications

Background: The liver cone unit (Tokyo 2020 terminology) of the peripheral portal vein territory represents the smallest anatomical and functional unit of the liver. While this unit enables anatomical, subsegmental resection, particularly in patients with cirrhosis, the tumor-bearing cone unit can be challenging to identify intraoperatively. PATIENTS AND METHODS: A 58-year-old man with hepatitis C-related cirrhosis (Child-Pugh B) was diagnosed with a subcapsular hepatocellular carcinoma (HCC) in segment 8.

View Article and Find Full Text PDF

Assessing the link between post-treatment ALT and HCC risk in chronic hepatitis C.

J Formos Med Assoc

September 2025

Department of Oncology, Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University, Ningbo, 315000, China. Electronic address:

View Article and Find Full Text PDF

Chronic hepatitis C mortality in Brazil from 2000 to 2019: An analysis of multiple causes of death.

Clinics (Sao Paulo)

September 2025

Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, SP, Brazil.

Introduction: Conventional mortality statistics that concentrate only on the underlying cause of death may offer a limited view of the complexity of this condition and not fully capture the true extent of mortality from hepatitis C.

Objective: To describe and analyze deaths due to chronic hepatitis C (CHC) in Brazil, as both a underlying and multiple cause of death, from 2000 to 2019.

Methods: This ecological study used data extracted from the Mortality Information System and descriptively analyzed causes of death and sociodemographic variables for the deceased.

View Article and Find Full Text PDF

Direct-acting antivirals (DAAs) have transformed hepatitis C virus (HCV) treatment in Australia since their inclusion on the Pharmaceutical Benefits Scheme (PBS) in 2016. Treatment has shifted from genotype-specific to pan-genotypic regimens, with glecaprevir/pibrentasvir and sofosbuvir/velpatasvir now recommended in clinical guidelines. This study examined trends in DAA dispensing in light of evolving treatment regimens.

View Article and Find Full Text PDF

Background And Aims: Sofosbuvir (SOF) plus daclatasvir (DCV) is a primary chronic hepatitis C virus (HCV) treatment in low- and middle-income countries. WHO guidelines recommend a half-adult dose for children (14-25 kg) based on pharmacokinetic modelling, requiring clinical validation. We evaluated the pharmacokinetics, safety, efficacy and acceptability of DCV (30 mg) and SOF (200 mg) in children weighing 14 to < 17 kg and 17-35 kg.

View Article and Find Full Text PDF